Related Experiment Video
Updated: Jan 13, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function
Nils Bessler1,2, Amber K L Wezenaar1,2, Hendrikus C R Ariese1,2
1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Abstract:
Diffuse midline glioma (DMG) is a highly aggressive and untreatable pediatric cancer primarily arising in the pontine brainstem region, necessitating the development of representative models for treatment advance. Here we developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered DMG. We demonstrated that brainstem pontine glial specification is critical for DMG tumorigenesis, yielding infiltrative tumors that recapitulate patient-representative intratumoral heterogeneity. Prolonged GD2 chimeric antigen receptor (CAR) T cell treatment mirrored clinical outcomes and revealed extensive transcriptional heterogeneity, from which both potent effector and dysfunctional CAR T cell populations could be identified. Furthermore, incorporation of myeloid cells generated DMG-specific microglia that reduced treatment efficacy and revealed CAR T cell functional states most vulnerable to microglia-mediated immunosuppression. Thus, we present a representative DMG model offering a months-long experimental window in vitro, which we leveraged to delineate CAR T cell functionality and microglial impact, aiding therapy development for this devastating disease.
Insights
Researchers developed a novel human brainstem organoid model for diffuse midline glioma (DMG), a pediatric cancer. This model revealed how microglia impact CAR T cell therapy efficacy, offering new avenues for treatment development.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Stem Cell Biology
Background:
- Diffuse midline glioma (DMG) is a fatal pediatric brain tumor with limited treatment options.
- Developing accurate preclinical models is crucial for understanding DMG pathogenesis and advancing therapies.
Purpose of the Study:
- To create a representative human brainstem organoid model for H3.3K27M-altered DMG.
- To investigate the efficacy and limitations of chimeric antigen receptor (CAR) T cell therapy in this model.
- To explore the role of myeloid cells, specifically microglia, in modulating treatment response.
Main Methods:
- Development of an FGF4-driven human brainstem organoid model.
- Genetic engineering of the organoid to model H3.3K27M-altered DMG.
- In vitro treatment with GD2 CAR T cells and myeloid cell co-culture.
- Analysis of tumor characteristics, CAR T cell responses, and microglial interactions using transcriptional profiling.
Main Results:
- The organoid model recapitulated key features of DMG, including pontine glial specification and intratumoral heterogeneity.
- Prolonged CAR T cell treatment showed variable outcomes, highlighting effector and dysfunctional T cell populations.
- Incorporated myeloid cells formed DMG-specific microglia that suppressed CAR T cell efficacy.
- Identified CAR T cell vulnerabilities to microglia-mediated immunosuppression.
Conclusions:
- The developed DMG organoid model provides a valuable platform for in vitro studies.
- The model elucidates CAR T cell dynamics and the immunosuppressive role of microglia in DMG.
- Findings offer insights for improving CAR T cell therapy strategies for pediatric brain tumors.
